The Journal of Urology
Volume 182, Issue 2 , Pages 728-734 , August 2009

CA9 Gene: Single Nucleotide Polymorphism Predicts Metastatic Renal Cell Carcinoma Prognosis

  • Michela de Martino

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Equal study contribution.
    • ,
  • Tobias Klatte

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Equal study contribution.
    • ,
  • David B. Seligson

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California
    • ,
  • Jeffrey LaRochelle

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Brian Shuch

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Randy Caliliw

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Zhenhua Li

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Fairooz F. Kabbinavar

      Affiliations

    • Department of Medicine, University of California-Los Angeles, Los Angeles, California
    • ,
  • Allan J. Pantuck

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Financial interest and/or other relationship with POM Wonderful, Novartis, Pfizer and Wilex.
    • ,
  • Arie S. Belldegrun

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Corresponding Author InformationCorrespondence: Division of Urologic Oncology, Department of Urology, University of California-Los Angeles, 650 Charles East Young Dr., Los Angeles, California 90095-1738 (telephone: 310-206-1434; FAX: 310-206-5343)

Received 28 October 2008

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  2. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289
  3. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559
  4. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496
  5. Ito N, Eto M, Nakamura E, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25:2785
  6. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67:9609
  7. Bachmann HS, Otterbach F, Callies R, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13:5790
  8. Decock J, Long JR, Laxton RC, et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67:10214
  9. Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, et al. Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms. Haematologica. 2007;92:1475
  10. Tse KP, Tsang NM, Chen KD, et al. MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res. 2007;13:6320
  11. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746
  12. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158:905
  13. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802
  14. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714
  15. Tripathi RT, Heilbrun LK, Jain V, et al. Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology. 2006;68:296
  16. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525
  17. Laws SM, Hone E, Gandy S, et al. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003;84:1215
  18. Capon F, Allen MH, Ameen M, et al. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet. 2004;13:2361
  19. Klatte T, Pantuck AJ. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008;35:573
  20. Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am. 2008;35:687

 Study received institutional review board approval.

 See Editorial on page 425.

PII: S0022-5347(09)00878-7

doi: 10.1016/j.juro.2009.03.077

The Journal of Urology
Volume 182, Issue 2 , Pages 728-734 , August 2009

Article Tools

* Image Usage & Resolution